Trial · NCT07557927
A Multicentre, Randomised, Double-blind, Positive-control Clinical Trial Evaluating Dihydroartemisinin Tablets for the Treatment of Discoid Lupus Erythematosus
NCT07557927, Phase 2, Not yet recruiting, Kunming Pharmaceuticals, Inc.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Multicentre, Randomised, Double-blind, Positive-control Clinical Trial Evaluating Dihydroartemisinin Tablets for the Treatment of Discoid Lupus Erythematosus. Trials, record NCT07557927. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07557927
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Multicentre, Randomised, Double-blind, Positive-control Clinical Trial Evaluating Dihydroartemisinin Tablets for the Treatment of Discoid Lupus Erythematosus
- NCT number
- NCT07557927
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 100 participants, estimated
- Lead sponsor
- Kunming Pharmaceuticals, Inc.
- Conditions
- Discoid Lupus Erythematosus
- Interventions
- Dihydroartemisinin tablets, Dihydroartemisinin tablets, Hydroxychloroquine tablets
- First posted
- 2026-04-30
- Last updated
- 2026-04-30
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage change from baseline in the Cutaneous Lupus Erythematosus Area and Severity Index (CLASI-A) score at week 24 | Week 24 | |
| Secondary | Percentage change from baseline in the Cutaneous Lupus Erythematosus Area and Severity Index (CLASI-A) score at weeks 2, 4, 8, 12, 16 and 20 | weeks 2, 4, 8, 12, 16 and 20 | |
| Secondary | Change in CLASI-A score from baseline | weeks 2, 4, 8, 12, 16, 20 and 24 | |
| Secondary | Percentage of participants with a ≥50% reduction in CLASI-A score from baseline (CLASI-50) | weeks 2, 4, 8, 12, 16, 20 and 24 | |
| Secondary | Percentage of participants with a ≥20% reduction in CLASI-A score from baseline | weeks 2, 4, 8, 12, 16, 20 and 24 | |
| Secondary | Percentage of participants with a 4-point reduction in CLASI-A activity score from baseline | weeks 2, 4, 8, 12, 16, 20 and 24 | |
| Secondary | Percentage of participants achieving a complete response (CR) in CLASI-A (defined as a score of '0') | weeks 2, 4, 8, 12, 16, 20 and 24 | |
| Secondary | Proportion of participants with a post-treatment DLQI (Dermatology Life Quality Index) score reduced by 2 points or more compared to baseline | weeks 2, 4, 8, 12, 16, 20 and 24 | |
| Secondary | Mean change in post-treatment DLQI (Dermatology Life Quality Index) score compared to baseline | weeks 2, 4, 8, 12, 16, 20 and 24 | |
| Secondary | Mean change in post-treatment PGA (Physician Global Assessment) score compared to baseline | weeks 2, 4, 8, 12, 16, 20 and 24 |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07557927
GET https://conductscience.org/api/trials/v1/NCT07557927/registered